AtaiBeckley drug shows sustained depression response in trial

April 8, 2026 6:00 AM

AtaiBeckley Inc. (NASDAQ: ATAI) reported that its experimental depression treatment BPL-003 achieved a 66.7% response rate by day two following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found